403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Multiplex PCR Kit Market Size To Lead At 10.64% CAGR By 2034
(MENAFN- GlobeNewsWire - Nasdaq) The global multiplex PCR kit market size was valued at USD 1.25 billion in 2024 and is predicted to hit around USD 3.43 billion by 2034, rising at a 10.64% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
![]()
Ottawa, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The global multiplex PCR kit market size
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @Key Takeaways
- Multiplex PCR kit market to crossed USD 1.25 billion by 2024. Market projected at USD 3.43 billion by 2034. CAGR of 10.64% expected in between 2025 to 2034. North America accounted for the dominating share of the market in 2024. Asia Pacific is expected to grow at the fastest CAGR in the studied years. By technology type, the real-time (qPCR) multiplex PCR segment led the market in 2024. By technology type, the digital multiplex PCR segment is expected to grow rapidly in the coming years. By product type, the multiplex PCR reagent kits segment dominated the market in 2024. By product type, the target-specific diagnostic panels segment is expected to be the fastest-growing in the predicted timeframe. By application, the infectious disease diagnostics segment held a major revenue share of the market in 2024. By application, the oncology and genetic mutation testing segment is expected to witness the fastest growth during 2025-2034.
What are the Ongoing Developments in the Multiplex PCR Kit?
The emergence of a diagnostic tool that enables the simultaneous detection of multiple DNA or RNA targets in a single reaction, employing a combination of various primers, is referred to as a multiplex PCR kit market. This market is further propelled by the rising infectious and chronic diseases, breakthroughs in diagnostic technologies, and the broader emphasis on tailored medicine. Recent milestones include an affordable multiplex quantitative RT-PCR (qRT-PCR) assay for identifying all four dengue virus (DENV) serotypes and chikungunya virus (CHIKV) in clinical samples, enabling accelerated disease surveillance and management in resource-limited areas.
You can place an order or ask any questions, please feel free to contact us at ...What are the Key Drivers in the Multiplex PCR Kit Market?
Impactful progression of the respective industry is mainly fueled by a rise in wider requirements for rapid and precise diagnostic results, specifically for pandemic surveillance and prior disease detection. Moreover, the persistent development in research especially in genomics
What are the Trends in the Multiplex PCR Kit Market?
- In November 2025, Primerdesign, a company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents, signed a distribution agreement with Scientific Laboratory Supplies (SLS) to boost the supply of Primerdesign's real-time PCR assays, reagents and workflows to academic research institutions in the UK. In October 2025, Bio-Rad Laboratories, Inc., a global company in life science research and clinical diagnostics products, and Gencurix, Inc., signed a strategic agreement for developing Bio-Rad as the exclusive distributor of Gencurix's CE-IVD Droplex digital PCR oncology testing kits across Europe. In September 2025, Japan's Hitachi High-Tech Corporation and Italy-based ELITechGroup S.p.A. collaborated on molecular testing for infectious diseases, including fully automated PCR testing systems and reagents for the European market.
What is the Emerging Challenge in the Market?
The need for greater initial spending for equipment and reagents, as well as the arising technical complexity in primer design and improvements, is creating a barrier to market expansion. Alongside, the involvement of stricter regulatory guidelines during the development and commercialisation of these advanced PCR kits is also impacting as an obstacle in the industry.
Become a valued research partner with us -Regional Analysis
Why did North America Dominate the Multiplex PCR Kit Market in 2024?
In 2024, North America captured the largest revenue share of the market. A prominent driver, along with the growing diverse disease cases, is the leveraging of government efforts in the US and Canada, such as the increased funding for R&D, which establishes a suitable landscape for the greater adoption of new diagnostic solutions like multiplex PCR. According to the CDC, there were nearly 10.2 million infectious and parasitic disease visits recorded to physician offices and 4.7 million to emergency departments in the US in 2024. In 2024, North American researchers designed a multiplex digital PCR (dPCR) based kit, known as Droplex NSCLC Panel Test Kit, for non-small cell lung cancer (NSCLC) patients.
How did the Asia Pacific hold a Notable Share of the Market in 2024?
In the coming years, the Asia Pacific is anticipated to expand rapidly in the multiplex PCR kit market. In the substantial countries, like China & India, are facing a huge rise in a variety of disease instances, such as the China's National Notifiable Disease Reporting System reported over 1.2 million cases of different infectious diseases in May 2024 alone, such as influenza (440,431), hand, foot, and mouth disease (226,183), and viral hepatitis (165,333). One of the significant advancements is the use of the U+ Probe qPCR Super PreMix, which was developed by Nanjing Vazyme Biotech Co., Ltd., in 2025 studies.
Segmental Insights
By technology type analysis
Which Technology Type Led the Multiplex PCR Kit Market in 2024?
The real-time (qPCR) multiplex PCR segment held a dominant share of the market in 2024. As they possess expanded throughput and effectiveness, which result in expenditure and time savings, with amplification of multiple targets at once, this is driving the initial growth. Also, recently, scientists created a two-tube multiplex real-time PCR assay for simultaneous differentiation among diverse clades and lineages of the mpox virus, which is vital for efficient surveillance and public health response.
Moreover, the digital multiplex PCR segment is predicted to witness rapid expansion. It has sensitivity in detecting rare mutations, mainly in cancer diagnostics and prenatal testing, with the detection of rare DNA in environmental samples is promoting future advances. Recent progressions encompass the Stilla Technologies' Naica System utilises a 6-color fluorescent scanner, which allows another dimension for highly multiplexed dPCR assays and SNP (Single Nucleotide Polymorphism) detection. In July 2025, Roche unveiled a Digital LightCycler as a prominent commercial platform.
Get the latest insights on life science industry segmentation with our Annual Membership:By product type analysis
Why did the Multiplex PCR Reagent Kits Dominate the Market in 2024?
By capturing the biggest share, the multiplex PCR reagent kits segment led the multiplex PCR kit market in 2024. The segment is driven by the rising disease cases and demand for high-throughput and efficient diagnostic solutions. Inclusion of innovations in reagent formulations (like lyophilized master mixes for feasible logistics), primer design quality, and automation-friendly platforms is also supporting the comprehensive developments.
Whereas the target-specific diagnostic panels segment will expand rapidly in the coming era. Ongoing emergence of faster detection of pathogens allows for the appropriate use of antibiotics, is supports the elimination of antimicrobial resistance (AMR). The latest effort comprises in April 2025, the U.S. FDA approved Breakthrough Device Designation to Roche's VENTANA TROP2 RxDx Device, an AI-assisted computational pathology assay focused on Non-Small Cell Lung Cancer (NSCLC). Additionally, the European Commission granted Roche's cobas Liat Respiratory Panel, a molecular diagnostic test for the simultaneous determination and differentiation of 16 respiratory viruses and influenza A and B.
By application analysis
Which Application Led the Multiplex PCR Kit Market in 2024?
The infectious disease diagnostics segment registered dominance in the market in 2024. According to official surveys, there were 14.1 million dengue cases, 10.7 million tuberculosis cases, and a resurgence of measles with approximately 11 million infections in the last year. Nowadays, the globe is leveraging cost-effective multiplex kits for co-infections, particularly Dengue and Chikungunya in resource-restricted settings, portable point-of-care devices for quicker diagnosis, and escalated panels for detecting bacterial and viral pathogens in a single reaction.
However, the oncology and genetic mutation testing segment is predicted to expand fastest. As per NIH, there will be nearly 20.3 million new cancer cases by 2030, which will boost the demand for more sophisticated diagnostic tools, assays, like PCR. Emerging advances are real-time and digital PCR, with improved sensitivity and speed, and the increasing use of non-invasive liquid biopsies is also influencing the overall expansionWhat are the Key Developments in the Multiplex PCR Kit Market?
- In November 2025, Servier India introduced inexpensive biomarker testing for Acute Myeloid Leukaemia (AML), an aggressive blood cancer and Cholangiocarcinoma (CCA), a rare bile duct cancer. In November 2025, Primerdesign (part of the Novacyt Group) launched its exsig Mag RapidBead Pro Extraction kit for the extraction of high-quality DNA and RNA from diverse sample types. In May 2025, Countable Labs (formerly Enumerix) launched Countable PCR, redefining what's possible with PCR for rare cases detection.
Browse More Insights of Towards Healthcare:
The global multiplex assay market size
The global multiplex PCR assay market
The global multiplex detection immunoassay market
The global DNA test kits market size
The global NGS kits market size
The global biotechnology reagents & kits market
The global in situ hybridization market
The global rapid medical diagnostic kits market
The global cancer biopsy market
The global point-of-care molecular diagnostics market
Multiplex PCR Kit Market Key Players List
- ThermoFischer Scientific Inc. Bio-Rad Laboratories Inc. Agilent Technologies Inc. Roche Molecular Systems Inc. Takara Bio Inc. Promega Corporation Illumina Inc. Meridian Bioscience Inc. Seegene Inc. GenScript Biotech Corp. Danaher Corporation (Beckman Colter/Cepheid) PerkinElmer Inc. Norgen Biotek Corp. Bioline (Meridian Life Science) New England Biolabs (NEB) Enzo Life Sciences Inc. Abcam plc Eurofins Genomics GeneFirst Ltd.
Segments Covered in the Report
By Technology Type
- Endpoint Multiplex PCR Real-Time (qPCR) Multiplex PCR Digital Multiplex PCR Reverse-Transcription Multiplex PCR (RT-Multiplex PCR) Hot-Start / Touchdown Multiplex PCR Others (nested, asymmetric, multiplex ligation-based)
By Product Type
- Multiplex PCR Master Mixes Multiplex PCR Reagent Kits (Primers, Enzymes, Buffers) Target-Specific Diagnostic Kits (Pathogen Panels, Cancer Panels) Multiplex PCR Consumables (Tubes, Plates, Seals) Others (Controls, Calibration Standards)
By Application
- Infectious Disease Diagnostics
- Respiratory Pathogen Panels Sexually Transmitted Infection (STI) Panels Gastrointestinal Pathogen Panels Blood-borne / Sepsis Pathogens Others
- Prenatal / Reproductive Health Testing Food & Water Safety Testing Forensic & Human Identification Veterinary Diagnostics Research & Academic Applications Others
By Region
- North America
- U.S. Canada
- China Japan India South Korea Thailand
- Germany UK France Italy Spain Sweden Denmark Norway
- Brazil Mexico Argentina
- South Africa UAE Saudi Arabia Kuwait
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment